Skip to main content
SpringerLink
Log in

Docetaxel/cisplatin confers QOL, survival benefits in NSCLC

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Docetaxel/cisplatin confers QOL, survival benefits in NSCLC. Pharmacoecon. Outcomes News 422, 10 (2003). https://doi.org/10.1007/BF03276559

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03276559

Keywords

Search

Navigation